- GlobeNewswire•4 days agoCyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
-Study did not reach statistically significant improvement in the primary endpoint of overall survival-. -Improvement in secondary endpoint of complete remission rate for the experimental arm-. -Conference ...
- GlobeNewswire•21 days ago
BERKELEY HEIGHTS, N.J., Feb. 06, 2017-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...
- GlobeNewswire•3 months agoCyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Potential in Esophageal Cancer and Acute Leukemia
BERKELEY HEIGHTS, N.J., Dec. 01, 2016-- Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer ...
CYCCP : Summary for Cyclacel Pharmaceuticals, Inc. - Yahoo Finance
Cyclacel Pharmaceuticals, Inc. (CYCCP)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Day's Range||5.05 - 6.40|
|52 Week Range||4.21 - 11.29|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.42|
|Dividend & Yield||0.60 (10.45%)|
|1y Target Est||N/A|